Unlocking the potential of gene therapy for patients with rare and orphan diseases

About Medgenics

At Medgenics, we share one singular focus - to transform the lives of our patients through the development of innovative and best-in-class therapies. We are dedicated to developing the our unique technology platform (TARGT) for the express purpose of treating patients with rare and orphan diseases.


TARGT has demonstrated several advantages over current gene or protein therapy, including efficacy, safety and capital efficiency.

Latest News

11-12-14 Medgenics Announces Rare & Orphan Disease Research Collaboration With The Children's Hospital of Philadelphia 10-15-14 Medgenics Reports Positive Initial Clinical Data and Third Quarter Financial Results 10-08-14 Medgenics to Host Conference Call to Announce Third Quarter 2014 Results and Provide Initial Clinical Data on MDGN-201 on October 15, 2014